Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
12.48B
Market cap12.48B
Price-Earnings ratio
-48.13
Price-Earnings ratio-48.13
Dividend yield
Dividend yield
Average volume
638.33K
Average volume638.33K
High today
High today
Low today
Low today
Open price
$206.96
Open price$206.96
Volume
0.00
Volume0.00
52 Week high
$219.30
52 Week high$219.30
52 Week low
$118.03
52 Week low$118.03

Stock Snapshot

Ascendis Pharma(ASND) stock is priced at $206.99, giving the company a market capitalization of 12.48B. It carries a P/E multiple of -48.13.

On 2025-11-17, Ascendis Pharma(ASND) shares started trading at $206.96, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 638.33K.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $219.30 and a low of $118.03.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $219.30 and a low of $118.03.

ASND News

Simply Wall St 2d
How Investors Are Reacting To Ascendis Pharma Achieving First Positive Operating Income and Pooled Data Milestone

Ascendis Pharma reported third-quarter 2025 results showing revenue of €213.63 million and a net loss of €60.99 million, with improved financial performance, gl...

How Investors Are Reacting To Ascendis Pharma Achieving First Positive Operating Income and Pooled Data Milestone
Simply Wall St 4d
Ascendis Pharma (NasdaqGS:ASND): Is There More Value Left After Strong Shareholder Returns?

Ascendis Pharma (NasdaqGS:ASND) has caught the attention of investors, with shares fluctuating over the past month. The company’s stock performance reflects shi...

Ascendis Pharma (NasdaqGS:ASND): Is There More Value Left After Strong Shareholder Returns?
TipRanks 4d
Ascendis Pharma: Promising Growth and Strong Market Penetration Justify Buy Rating

Analyst Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma and increased the price target to $220.00 from $212.00. Meet Your ETF AI Analyst Disco...

Analyst ratings

100%

of 15 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

TipRanks 5d
Ascendis Pharma Grants Warrants to Employees in Strategic Move

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

TipRanks 5d
Ascendis Pharma reports Q3 EPS vs. last year

Reports Q3 revenue EUR 213.63M vs. EUR 57.83M last year. “With our achievements in the third quarter and year to date, Ascendis is making great progress toward...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.